Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Risk communication AC meeting

This article was originally published in The Tan Sheet

Executive Summary

FDA will hold a public meeting of the Risk Communication Advisory Committee on Feb. 28 and 29 at the Washington, D.C. North/Gaithersburg, Md. Hilton, the agency announces in a Feb. 8 Federal Register notice. The committee will meet the first day from 8 a.m. to 5 p.m. for presentations and discussion of the relation of the agency's risk communication programs and FDA's responsibilities. The committee will continue on the second day from 8 a.m. to 4 p.m. with presentations and discussion of FDA's proposed template for product recall press releases, the agency says...

You may also be interested in...



Plexxikon Wins Tafinlar Patent Dispute Case Against Novartis

The Daiichi Sankyo affiliate successfully argued that Novartis willfully infringed two patents covering its discoveries in the BRAF inhibitor drug class, getting nearly $178m in damages and future royalties.

Adverum Faces Rocky Road As It Switches Gears From DME To Wet AMD

Adverum said it would cease developing ADVM-022 for DME and focus on wet AMD, but the adverse events that prompted the shift could invite further scrutiny in an already competitive market.

Abbott’s Q2 Medical Device And Diagnostic Sales Surpass 2019 Levels

Abbott expects the ongoing recovery of medical procedure volumes to continue even as new virus variants are causing COVID-19 cases to increase in some geographies.

Topics

UsernamePublicRestriction

Register

PS101356

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel